The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate prescription drug prices, a sign that some consumer advocates said suggests the Trump administration is willing to maintain the controversial program.

Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling that the controversial program introduced by former President Biden will continue under President Trump’s new administration.

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it selected for negotiation.

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be made and what changes they would like to see.

The Trump administration is moving forward with the defense of a Biden-era plan that allows Medicare to negotiate drug prices against Novartis AG’s appeal at the Third Circuit.

The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future of the IRA’s

President Donald Trump will meet with major drugmakers' executives to discuss drug pricing and insurance changes. Key topics include Medicare price negotiations, pharmacy benefit management, and potential tariffs on pharmaceuticals.

The industry is also pushing for curbs on the rebates they pay pharmacy benefit managers, which act as middlemen between drug companies and consumers, in exchange for favorable pl

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy benefit managers (PBMs),